STIEFEL LABORATORIES ANNOUNCES THE EXPANSION OF ITS REVALÉSKIN® SKIN CARE LINE WITH THREE NEW PRODUCTS

Bob Cunard appointed President of Glades Pharmaceuticals

Stiefel Laboratories Completes Acquisition of Barrier Therapeutics

STIEFEL LABORATORIES, INC. SUCCESSFULLY COMPLETES TENDER OFFER FOR SHARES OF BARRIER THERAPEUTICS, INC.

STIEFEL LABORATORIES, INC. ANNOUNCES EXPIRATION OF HART-SCOTT-RODINO WAITING PERIOD RELATING TO ITS PROPOSAL TO ACQUIRE BARRIER THERAPEUTICS, INC.

Stiefel Laboratories, Inc. Commences Tender Offer to Acquire Barrier Therapeutics, Inc.

Barrier Therapeutics to Merge Into Stiefel Laboratories

Stiefel Laboratories, Inc. Acquires ABR Invent and ABR Development

Stiefel Laboratories Appoints First Chief Scientific Officer

Stiefel Laboratories Joins Hollywood A-Listers in Support of Epidermolysis Bullosa Medical Research Foundation Pledges up to $1 million for awareness and research

Stiefel Laboratories Announces Senior Staff Promotions

Stiefel Laboratories, Inc. Appoints New President

Stiefel Laboratories, Inc. Announces Global Staff Hires and Promotions

Stiefel Laboratories, Inc. Enters into Strategic Collaboration with Allergan, Inc. to Expand and Strengthen Dermatologic Product Offering

Stiefel Laboratories Appoints Two New Members to Board of Directors

Stiefel Canada, Inc. Appoints Pierre Boucher Executive Vice President

Stiefel Laboratories, Inc. To Keep Former Connetics Facility Open

Stiefel Laboratories Appoints Jim Loerop to Lead Global Corporate Development

Eaglstein Earns Sixth Annual John Boswick Memorial Award and Lectureship

Stiefel Laboratories Appoints Gavin Corcoran to Lead Global Research and Development

Stiefel Laboratories Will Enter Into Private Equity Minority Investment Agreement with The Blackstone Group

FDA Approves Extina® for the Treatment of Seborrheic Dermatitis

Stiefel Laboratories, Inc. Announces New Brevoxyl Acne Wash Kit Now Available

First Clinical Data for REVALÉSKIN featuring POWERFUL NATURAL ANTIOXIDANT CoffeeBerry Revealed

Stiefel Laboratories Officially Joins Prestigious Research Triangle Park Community

Stiefel Laboratories Moves to Solidify, Enhance Its Leadership Position in Dermatology

Stiefel Laboratories, Inc. Donates First Dermatology Ward in Tanzania, East Africa

Stiefel Laboratories, Inc. Appoints Richard J. MacKay Vice Chairman of the Board of Directors

Stiefel Laboratories receives FDA approval of OLUX-E(Clobetasol Propionate) Foam, 0.05% for treatment of psoriasis and eczema

Connetics Corporation Announces Holders' Right to Require the Repurchase of 2.00% Convertible Senior Notes Due 2015

Connetics Corporation Announces Holders' Right to Require the Repurchase of 2.25% Convertible Senior Notes Due 2008

Stiefel Laboratories, Inc. Completes Acquisition of Connetics Corporation

Stiefel Laboratories, Inc. Appoints Larry Staubach, M.D., M.B.A.
Vice President, Global Medical Affairs and Pharmacovigilance

Stiefel Laboratories, Inc. Announces New Facility in Atlanta Metro Area

Bill Humphries joins the Board of Directors at Stiefel Laboratories, Inc.

CEO of 159-year old Company Nominated for National Ernst & Young Entrepreneur Of The Year Award

Dermatological Expert Dr. William Eaglstein Appointed Vice President, R&D Pipeline Development & Scientific Affairs

Connetics Corporation to Merge Into Stiefel Laboratories Inc. Strategic combination to create world's premier dermatology company

Jeff Thompson Takes on New Leadership Role at Stiefel Laboratories, Inc. as the Company Looks toward 160th Anniversary Year

Stiefel Laboratories, Inc. Announces Duac Topical Gel Now Available in Italy

Stiefel Laboratories, Inc. Endows Chair In Medical Dermatology

New Larger Size of MimyX Cream Introduced

Stiefel Laboratories, Inc. Announces Licensing Agreement

STIEFEL LABORATORIES APPOINTS ALFONSO UGARTE, VICE PRESIDENT GLOBAL MARKETING

STIEFEL LABORATORIES APPOINTS JIM LOEROP, VICE PRESIDENT U.S. CORPORATE DEVELOPMENT

Stiefel Laboratories, Inc. Announces Purchase of New Global R&D Facility In Research Triangle Park

Study Shows New Atopic Dermatitis Therapy Significantly Delays Onset of Flares

STIEFEL LABORATORIES APPOINTS DR. GAVIN CORCORAN, VICE PRESIDENT, GLOBAL CLINICAL RESEARCH AND REGULATORY AFFAIRS

STIEFEL LABORATORIES, INC. APPOINTS WILLIAM A. CARR, JR., SENIOR VICE PRESIDENT, GLOBAL OPERATIONS

New Product Cleared By FDA Takes Novel Approach To Atopic Dermatitis Millions affected by chronic skin disease could benefit from new product

Stiefel Laboratories and Grupo Uriach Enter Licensing Agreement for Innovative Molecule

NEW FOAM PRODUCT FOR THE TREATMENT OF SCABIES A DEVELOPMENT COLLABORATION BYSTIEFEL LABORATORIES, Inc. of the USA and FOAMIX LTD. of Israel

DEL-RAY DERMATOLOGICALS® and STIEFEL LABORATORIES, INC. ANNOUNCE A CO-PROMOTION AGREEMENT TO MARKET BLUE LIZARD® AUSTRALIAN SUNCREAM TO PEDIATRICIANS

Stiefel Laboratories, Inc. Announces Appointment of Dr. Marco Taglietti, MD, to The Newly Created Position Of Senior Vice President, Head of Global Research and Development